Modified Bis-amide Derivatives as Protease inhibitors for treatment of Covid-19

Back to all technologies
Download as PDF
2021-GHOS-69206
Researchers at Purdue University have developed a new class of noncovalent functionalized bis-amide inhibitors for treatment of Covid-19.

There remains an ongoing global health pandemic which has now affected over 170 million people to date and there is no available therapeutic option. The compounds developed by Purdue researchers in this disclosure are newer modified versions of bis-amide derivatives that have demonstrated potent inhibitory effect on SARS-CoV-2 enzyme, 3CLpro. These inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections.

Advantages:
-Potent Covid-19 Antiviral Properties
-Improved Drug-Like Features

Potential Applications:
-Treatment of SARS-CoV-2
-Pharmaceutical Research and Development
-Pandemic Control

Technology Validation:
The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.
Dec 1, 2020
Provisional-Gov. Funding
United States
(None)
(None)

(None)
PCT-Gov. Funding
WO
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org